Biodeal Pharmaceuticals Limited - Company Profile

It is a pharma public limited company based in Nalagarh, Distt. Solan (Hp)., Himachal Pradesh, India, established in 2005.
2005 Nalagarh, Distt. Solan (Hp)., Himachal Pradesh, India Active
Last Updated:
Access Report
About Biodeal Pharmaceuticals Limited

Biodeal Pharmaceuticals Limited, a active public limited company, was established on 30 December 2005 in Nalagarh, Distt. Solan (Hp)., Himachal Pradesh, India. Engaging in drug formulation & development within the manufacturing sector, it holds CIN: U00304HP2005PLC029451. Registered under ROC Roc Himachal Pradesh. it is unlisted. It has an authorized capital of ₹25.45 Cr and a paid-up capital of ₹25.34 Cr.

It upholds a compliant status. Employing 343 professional, Its leadership includes Dev Datt (Director), Anurag Kumar (Managing Director), Anchal Kumari (Director). Past directors included Gurudutta Mishra, Dev Datt, Swati Tiwari. It holds ₹212.08 Cr open charges and ₹122.92 Cr settled loans. Its latest AGM occurred on 30 September 2025, with the balance sheet filed on 31 March 2025. It is based at Village Saini Majra,Nalagarh-Ropar Road, Teh. Nalagarh, Distt. Solan (Hp)., Nalagarh, Distt. Solan (Hp)., Himachal Pradesh.

Company Details
  • Email
    **********
  • Telephone

    +91-XXXXXXXXXX

  • Website
    **********
  • Social Media
    **********
  • Apps
    **********

Company Details

  • CIN/LLPIN

    U00304HP2005PLC029451

  • Registration Number

    029451

  • Incorporation Date

    30 December 2005

  • Authorized Capital

    ₹25.45 Cr

  • Paid-Up Capital

    ₹25.34 Cr

  • ROC Code

    Roc Himachal Pradesh

  • Listing Status

    Unlisted

  • Company Status

    Active

Key Metrics
  • Authorised Capital ₹ 25.45 Cr
  • Paid Up Capital ₹ 25.34 Cr
  • Company Age 20 Year, 2 Months
  • Last Filing with ROC 31 Mar 2025
  • Open Charges ₹ 212.08 Cr
  • Satisfied Charges ₹ 122.92 Cr
  • Revenue Growth **** 41.92%
  • Profit Growth **** 90.53%
  • Ebitda **** 177.98%
  • Net Worth 21.33%
  • Total Assets **** 74.26%
Company report

Biodeal Pharmaceuticals Limited

Company Report FY 2025-2026

Comprehensive Company Insights

Explore comprehensive insights into Biodeal Pharmaceuticals Limited — covering financial performance, compliance records, Competitor, shareholding patterns, directors, key metrics, and litigation history. Unlock to see detailed insights and stay informed.

Access Report
Who are the key members and board of directors at Biodeal Pharmaceuticals Limited?
Current Directors
Name Designation Appointment Date Status
Dev Datt Director 01 Apr 2021 Current
Anurag Kumar Managing Director 31 Dec 2020 Current
Anchal Kumari Director 30 Nov 2022 Current
Noopur Jha Director 14 Jun 2024 Current
Abhishek Jain Nominee Director 16 May 2025 Current
Adheesh Chander Malhotra Additional Director 20 Jun 2025 Current
Past Directors
Name Designation Cessation Status
Pramod Abcsdd Nominee Director 24 Apr 2025 Past
Pramod Abcsdd Whole-Time Director 31 Oct 2023 Past
Pramod Abcsdd Company Secretary - Past
Pramod Abcsdd Director 14 Mar 2023 Past
Pramod Abcsdd Additional Director 27 Apr 2023 Past
Pramod Abcsdd Company Secretary - Past

Discover detailed profiles of directors and KMP - Unlock leadership insights today!

Financial Performance of Biodeal Pharmaceuticals.

Biodeal Pharmaceuticals Limited, for the financial year ended 2024, experienced significant growth in revenue, with a 41.92% increase. The company also saw a substantial improvement in profitability, with a 90.53% increase in profit. The company's net worth Soared by an impressive increase of 21.33%.

Biodeal Pharmaceuticals revenue growth over time
Biodeal Pharmaceuticals profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors
Emtek
Feb, 2021 Amount Post-IPO - Grab Valuation

investors
Signite Partners
Jan, 2021 Amount Post-IPO - Grab Valuation

investors
Hana Financial Group , GGV Capital
Feb, 2021 Amount Post-IPO - Grab Valuation

investors
Signite Partners
  • Key Matrics
  • Balance Sheet
  • Profit and Loss
  • Cash Flow
  • Ratios
Metrics
(FY 2023) YOY Growth
(FY 2022) (FY 2021) (FY 2020) (FY 2019)
Total Revenue
********
 41.92%
*******
*******
*******
*******
Revenue from Operations
*******
 41.32%
*******
*******
*******
*******
Total Assets
*******
 74.26%
*******
*******
*******
*******
Profit or Loss
*******
 90.53%
*******
*******
*******
*******
Net Worth
*******
 21.33%
*******
*******
*******
*******
EBITDA
*******
 177.98%
*******
*******
*******
*******

Discover detailed financial data and - Unlock financial today!

What is the Ownership and Shareholding Structure of Biodeal Pharmaceuticals?

In 2024, Biodeal Pharmaceuticals had a promoter holding of 99.88% and a public holding of 0.12%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.

Shareholding Pattern (FY 2024)
shareholding
  • Promoters: 92.83%
  • Public: 4.10%
  • Others: 3.07%
Shareholding Pattern over the Year
FY (2024) FY (2023) FY (2022) FY (2021) FY (2020)
Promoters 92.83 94.62 94.55 94.55 94.55
Public 4.10 3.89 3.95 3.96 3.98
Others 3.07 1.49 1.50 1.49 1.47

Reveal ownership structures and financial performance - Get instant access now!

Charges (Loans)
Open Charges

₹2,120,845,000.00

Satisfied Charges

₹1,229,182,431.00

Charges Breakdown by Lending Institutions
  • Others : 110.00 Cr
  • Yes Bank Limited : 50.00 Cr
  • Axis Bank Limited : 50.00 Cr
  • Hdfc Bank Limited : 2.08 Cr
Latest Charge Details
Date Lender Amount Status
18 Oct 2025 Axis Bank Limited ₹50.00 Cr Open
25 Sep 2025 Hdfc Bank Limited ₹1.31 Cr Open
29 Aug 2025 Hdfc Bank Limited ₹3.14 M Open
06 May 2025 Hdfc Bank Limited ₹1.14 M Open
21 Feb 2025 Hdfc Bank Limited ₹2.46 M Open

Explore comprehensive loan charge details -

How Many Employees Work at Biodeal Pharmaceuticals?

Biodeal Pharmaceuticals has a workforce of 343 employees as of Apr 10, 2025. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.

Employee Date Number of Employees
2020 78,000
2021 80,500
2022 83,200
2023 86,000
2024 89,500
2025 92,000
Deals i
Graph showing company valuation over time

Gain comprehensive insights into the Deals and Valuation data of Biodeal Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Biodeal Pharmaceuticals's trajectory.

Rating
Graph displaying rating trends over time

Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.

Alerts
Alert Indicator

Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.

Explore deal ratings and alerts - Get instant access now!

Latest Updates, News, and FAQs on Biodeal Pharmaceuticals
Recent Activity within the Organization
  • Charges

    A charge registered on 18 Jan 2022 via Charge ID 100527051 with Sidbi was fully satisfied on 20 Nov 2025. was recorded as a recent event.

  • Director Appointment

    The activity Sanjay Kumar Sharma was appointed as a Ceo was appointed as a Ceo on 07 Nov 2025 & has been associated with this company since 4 months 1 day . was completed.

  • Charges

    Progress on A charge with Axis Bank Limited amounted to Rs. 50.00 Cr with Charge ID 101182326 was registered on 18 Oct 2025. was documented.

  • Director Appointment

    Progress on Rishi Kapoor was appointed as a Cfo was appointed as a Cfo on 04 Oct 2025 & has been associated with this company since 5 months 4 days . was documented.

  • Annual General Meeting

    Biodeal Pharmaceuticals Limited last Annual general meeting of members was held on 30 Sep 2025 as per latest MCA records. was recorded as a recent event.

  • Charges

    Progress on A charge with Hdfc Bank Limited amounted to Rs. 1.31 Cr with Charge ID 101188927 was registered on 25 Sep 2025. was documented.

Explore recent activity and updates - View Recent Activity

Frequently Asked Questions
What is the CIN of Biodeal Pharmaceuticals Limited?

The CIN of Biodeal Pharmaceuticals Limited is U00304HP2005PLC029451.

Where is Biodeal Pharmaceuticals Limited headquartered?

Biodeal Pharmaceuticals Limited is headquartered at Village Saini Majra,Nalagarh-Ropar Road, Teh. Nalagarh, Distt. Solan (Hp)., Nalagarh, Distt. Solan (Hp)., Himachal Pradesh.

When was Biodeal Pharmaceuticals Limited incorporated?

Biodeal Pharmaceuticals Limited was incorporated on 30 December 2005.

Who are the current directors of Biodeal Pharmaceuticals Limited?

The current directors of Biodeal Pharmaceuticals Limited are

What is the primary industry of Biodeal Pharmaceuticals Limited?

The primary industry of Biodeal Pharmaceuticals Limited is Manufacturing.

Is Biodeal Pharmaceuticals Limited a listed company?

Biodeal Pharmaceuticals Limited is unlisted.

What is the capital structure of Biodeal Pharmaceuticals Limited?

The authorized capital of Biodeal Pharmaceuticals Limited is ₹25.45 Cr, and the paid-up capital is ₹25.34 Cr.

What is the compliance status of Biodeal Pharmaceuticals Limited?

The compliance status of Biodeal Pharmaceuticals Limited is Compliant.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available